Phospholipase C Beta 2 as a Key Regulator of Tumor Progression and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Renal Cell Carcinoma
Open Access
- 26 January 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 304
Abstract
Background: Renal cell carcinoma (RCC) represents the most common form of invasive kidney cancer in adults. Among the components critical to cellular regulation is Phospholipase C Beta 2 (PLCB2), a member of the phospholipase C enzyme family. This enzyme plays a vital role in managing key cellular functions such as growth, differentiation, migration, and survival. Despite its significant importance, the specific expression patterns and molecular mechanisms of PLCB2 in the progression of RCC are not well understood. Methods: This investigation employed a combination of bioinformatics analyses, scRNA-seq, functional assays, transcriptome sequencing, real-time quantitative PCR (RT-PCR), immunofluorescence, rescue experiments, and Western blotting to explore the regulatory function of PLCB2 in driving the epithelial-mesenchymal transition (EMT) in RCC through the PI3K/AKT signaling pathway. Results:PLCB2 expression is significantly elevated in RCC samples, and this increase is inversely correlated with patient prognosis. The knockdown of PLCB2 in RCC cell lines leads to a marked reduction in cell proliferation, invasion, migration, and EMT. Transcriptome sequencing further revealed that PLCB2 is significantly associated with the PI3K/AKT pathway. Notably, the PI3K activator 740Y-P was able to reverse the reductions in migration, invasion, and EMT caused by the PLCB2 knockdown. Conclusions: Our findings underscore the pivotal role of PLCB2 in regulating RCC invasion and metastasis by modulating the EMT via the PI3K/AKT signaling pathway. This highlights PLCB2 not only as a key prognostic biomarker, but also as a promising therapeutic target in the treatment of advanced-stage RCC, offering new avenues for more effective interventions.Keywords
Funding Information
- Scientific Research Fund of Liaoning Provincial Education Department (JYTMS20230577)
- Youth Talent Cultivation Fund Project of Dalian Medical University (JYTMS20230577)
This publication has 59 references indexed in Scilit:
- TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor MicroenvironmentThe American Journal of Pathology, 2024
- European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 UpdateEuropean Urology, 2023
- Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compoundsMedicinal Research Reviews, 2023
- Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into OpportunitiesEuropean Urology, 2022
- Wnt signaling pathway in cancer immunotherapyCancer Letters, 2022
- Targeting Wnt/β‐catenin and PI3K/Akt/mTOR pathways in T‐cell acute lymphoblastic leukemiaJournal of Cellular Physiology, 2020
- Epithelial-Mesenchymal Plasticity in Cancer Progression and MetastasisDevelopmental Cell, 2019
- Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic ModalitiesCell, 2017
- CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradationBiochemical and Biophysical Research Communications, 2017
- Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44+ Gastric Cancer Stem CellsStem Cells Translational Medicine, 2017